Literature DB >> 20725708

[Aspirin-Intolerance-Syndrom : a common and interdisciplinary disease].

C Umbreit1, J C Virchow, C Thorn, K Hörmann, L Klimek, O Pfaar.   

Abstract

The full clinical picture of aspirin intolerance - the association of aspirin-induced bronchial asthma, aspirin sensitivity and nasal polyps - has been described as Morbus Widal or later as the "Samter triad". Today the term Aspirin-exacerbated respiratory disease (AERD) is preferred to account for the progressive nature of this inflammatory airway condition with its unrelenting course even in the absence of non steroidal anti-inflammatory drugs (NSAID). This acquired idiosyncrasy appears to be related to an abnormal arachidonic acid metabolism. Epidemiological data suggests that 10% of all asthmatics do react with life-threatening asthma-attacks after the ingestion of aspirin (ASA) or other NSAID. Some asthmatics with nasal polyposis have been reported to suffer from aspirin intolerance. Although the exact mechanism is still unclear, it is unlikely that the pathogenesis is IgE-mediated. Patients often report chronic nasal obstruction, hyposmia, chronic rhinorrhoea, orbital edema and urticaria with flushing after the ingestion of NSAID. While a typical history and endoscopic findings can be suggestive of AERD, a definite diagnosis relies on appropriate challenge tests. AERD is often refractory to standard asthma treatment with systemic and inhaled steroids, β(2)-agonists, leukotrien-antagonists. Adaptive desactivation can induce a reversible tolerance to NSAID which also leads to an improvement in signs and symptoms of the underlying AERD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20725708     DOI: 10.1007/s00108-010-2661-y

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  29 in total

Review 1.  Treatment of asthma with antileukotrienes: first line or last resort therapy?

Authors:  Sven-Erik Dahlén
Journal:  Eur J Pharmacol       Date:  2006-02-28       Impact factor: 4.432

2.  Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.

Authors:  A S Cowburn; K Sladek; J Soja; L Adamek; E Nizankowska; A Szczeklik; B K Lam; J F Penrose; F K Austen; S T Holgate; A P Sampson
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

3.  Intolerance to aspirin. Clinical studies and consideration of its pathogenesis.

Authors:  M Samter; R F Beers
Journal:  Ann Intern Med       Date:  1968-05       Impact factor: 25.391

4.  Intranasal lysine-aspirin in aspirin-sensitive nasal polyposis: a controlled trial.

Authors:  Abhi A Parikh; Glenis K Scadding
Journal:  Laryngoscope       Date:  2005-08       Impact factor: 3.325

Review 5.  Cellular allergen stimulation test (CAST) 2003, a review.

Authors:  A L de Weck; M L Sanz
Journal:  J Investig Allergol Clin Immunol       Date:  2004       Impact factor: 4.333

Review 6.  Aspirin intolerance and nasal polyposis.

Authors:  César Picado
Journal:  Curr Allergy Asthma Rep       Date:  2002-11       Impact factor: 4.806

7.  Means of increasing sensitivity of an in vitro diagnostic test for aspirin intolerance.

Authors:  A May; A Weber; H Gall; R Kaufmann; T M Zollner
Journal:  Clin Exp Allergy       Date:  1999-10       Impact factor: 5.018

Review 8.  Aspirin desensitization in aspirin intolerance: update on current standards and recent improvements.

Authors:  Oliver Pfaar; Ludger Klimek
Journal:  Curr Opin Allergy Clin Immunol       Date:  2006-06

9.  Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily.

Authors:  A Rozsasi; D Polzehl; T Deutschle; E Smith; K Wiesmiller; H Riechelmann; T Keck
Journal:  Allergy       Date:  2008-09       Impact factor: 13.146

Review 10.  EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity.

Authors:  E Nizankowska-Mogilnicka; G Bochenek; L Mastalerz; M Swierczyńska; C Picado; G Scadding; M L Kowalski; M Setkowicz; J Ring; K Brockow; C Bachert; S Wöhrl; B Dahlén; A Szczeklik
Journal:  Allergy       Date:  2007-05-22       Impact factor: 13.146

View more
  5 in total

1.  Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)?

Authors:  Ludger Klimek; Ralph Dollner; Oliver Pfaar; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2014-06       Impact factor: 4.806

2.  [Guideline for "rhinosinusitis"-long version : S2k guideline of the German College of General Practitioners and Family Physicians and the German Society for Oto-Rhino-Laryngology, Head and Neck Surgery].

Authors:  B A Stuck; A Beule; D Jobst; L Klimek; M Laudien; M Lell; T J Vogl; U Popert
Journal:  HNO       Date:  2018-01       Impact factor: 1.284

3.  [ASA-intolerance syndrome and persistent rhinosinusitis : Differential diagnosis and treatment].

Authors:  H Kirsche; L Klimek
Journal:  HNO       Date:  2015-05       Impact factor: 1.284

4.  Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study.

Authors:  V Gudziol; M Michel; C Sonnefeld; D Koschel; T Hummel
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-11-09       Impact factor: 2.503

5.  [Aspirin desensitization: therapy options in patients with aspirin-exacerbated respiratory disease].

Authors:  R Weber; A Trautmann; W Randerath; W Heppt; W Hosemann
Journal:  HNO       Date:  2012-04       Impact factor: 1.284

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.